BluMaiden utilizes artificial intelligence (AI) to revolutionize small-molecule drug discovery by streamlining the process of designing new drugs. By harnessing AI algorithms, BluMaiden efficiently analyzes massive amounts of data to predict how molecules will interact with biological targets, enabling the identification of potential drug candidates more quickly and accurately. This innovative approach has the potential to significantly accelerate the development of new medications and improve treatment options for various diseases.
Source link
Puma’s new boss takes helm trailing Adidas and a recovering Nike
Puma's leadership has aimed to elevate the brand's image for over two years, focusing on making its sneakers and apparel more aspirational. However, new CEO Arthur Hoeld has indicated that the brand is now perceived as cheap, suggesting a disconnect between the company's goals and public perception. Want More Context? 🔎
Read more